Trade

with

Curis Inc
(NASDAQ: CRIS)
AdChoices
1.32
-0.03
-2.22%
After Hours :
1.31
-0.01
-0.76%

Open

1.30

Previous Close

1.35

Volume (Avg)

138.68k (591.99k)

Day's Range

1.28-1.36

52Wk Range

1.19-4.43

Market Cap.

113.53M

Dividend Rate ( Yield )

-

Beta

2.27

Shares Outstanding

86.00M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 15.00M

    • Net Income

    • -12.32M

    • Market Cap.

    • 113.53M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -91.31

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.27

    • Forward P/E

    • -6.00

    • Price/Sales

    • 7.58

    • Price/Book Value

    • 2.88

    • Price/Cash flow

    • -7.74

      • EBITDA

      • -8.34M

      • Return on Capital %

      • -19.04

      • Return on Equity %

      • -37.48

      • Return on Assets %

      • -19.04

      • Book Value/Share

      • 0.46

      • Shares Outstanding

      • 86.00M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 6.50

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.19

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -11.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 12.39

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 98.10

            • 82.75

            • Pre-Tax Margin

            • -91.31

            • 39.38

            • Net Profit Margin

            • -91.31

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 99.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -77.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.62

              • 0.76

              • Current Ratio

              • 6.14

              • 2.92

              • Quick Ratio

              • 6.11

              • 2.35

              • Interest Coverage

              • -2.53

              • 38.02

              • Leverage Ratio

              • 1.88

              • 2.21

              • Book Value/Share

              • 0.46

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.73

                • 217.39

                • P/E Ratio 5-Year High

                • -35.51

                • 634.30

                • P/E Ratio 5-Year Low

                • -7.48

                • 124.82

                • Price/Sales Ratio

                • 7.97

                • 9.52

                • Price/Book Value

                • 3.03

                • 8.61

                • Price/Cash Flow Ratio

                • -7.74

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -37.48

                    (-27.50)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -19.04

                    (-20.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -14.63

                    (-22.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.21

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -9.42M
                  Operating Margin
                  -62.77
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.74
                  Ownership

                  Institutional Ownership

                  50.08%

                  Top 10 Institutions

                  40.28%

                  Mutual Fund Ownership

                  13.00%

                  Float

                  76.87%

                  5% / Insider Ownership

                  2.25%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Monks

                  •  

                    2,493,600

                  • 0.00

                  • 2.90

                  • Worldwide Healthcare

                  •  

                    1,950,100

                  • 0.00

                  • 2.28

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,534,909

                  • 0.00

                  • 1.78

                  • iShares Nasdaq Biotechnology

                  •  

                    1,114,751

                  • -0.47

                  • 1.24

                  • Vanguard Extended Market Index Fund

                  •  

                    999,257

                  • 0.47

                  • 1.16

                  • FCP OP MEDICAL BioHealthTrends

                  •  

                    409,500

                  • 152.00

                  • 0.46

                  • Franklin Biotechnology Discovery

                  •  

                    409,200

                  • 0.00

                  • 0.48

                  • Vanguard Instl Total Stock Market Index

                  •  

                    308,961

                  • 0.00

                  • 0.36

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    272,013

                  • 0.00

                  • 0.32

                  • iShares Micro-Cap

                  •  

                    256,135

                  • 0.00

                  • 0.29

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    19,468,451

                  • +8.54%

                  • 22.64

                  • Baillie Gifford & Co Limited.

                  •  

                    3,154,100

                  • 0.00%

                  • 3.67

                  • Vanguard Group, Inc.

                  •  

                    2,856,767

                  • -5.21%

                  • 3.32

                  • BlackRock Fund Advisors

                  •  

                    2,284,174

                  • -29.15%

                  • 2.66

                  • Orbimed Advisors, LLC

                  •  

                    1,950,100

                  • 0.00%

                  • 2.27

                  • OrbiMed Advisor LLC

                  •  

                    1,950,100

                  • 0.00%

                  • 2.28

                  • Franklin Advisers, Inc.

                  •  

                    934,300

                  • 0.00%

                  • 1.09

                  • Northern Trust Investments, N.A.

                  •  

                    885,725

                  • -20.27%

                  • 1.03

                  • Millennium Management LLC

                  •  

                    531,903

                  • +858.44%

                  • 0.62

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Curis, Inc., was organized as a Delaware corporation on February 14, 2000. It began its operations in July 2000 upon the completion of the merger of Creative BioMolecules, Inc., Ontogeny, Inc. and Reprogenesis, Inc. The Company is a ...moredrug discovery and development company that leverages its signaling pathway drug technologies to develop next generation targeted cancer therapies. The Company’s advanced program is its Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly-owned member of the Roche Group. The drug candidate being developed under this program is Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor, which is also referred to as vismodegib, GDC-0449 and RG3616. Erivedge is designed to selectively inhibit signaling in the Hedgehog pathway...more by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. In addition to the BCC clinical trials being conducted directly by Genentech and Roche, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech and either third-party investigators or the U.S. National Cancer Institute. In addition to the ongoing clinical trials that Genentech and Roche are conducting, Genentech and the National Cancer Institute, entered into a collaborative relationship that allows the NCI to study GDC-0449 in additional potential cancer indications. The Company has in the U.S., 97 issued or allowed patents. The Company’s competitors include large pharmaceutical and biopharmaceutical companies, as well as specialized biotechnology firms, that are developing cancer therapies in the same indications as it is. The Company is subject to government regulations.lessless

                  Key People

                  Dr. Ali Fattaey

                  President/CEO/Director

                  Daniel R. Passeri

                  Vice Chairman of the Board/Director

                  James R. Mcnab,Jr

                  Chairman of the Board/Director

                  Michael P. Gray

                  CFO/Chief Accounting Officer/Secretary/Other Executive Officer

                  Dr. Jaye Viner

                  Chief Medical Officer/Executive VP

                  • Curis Inc

                  • 4 Maguire Road

                  • Lexington, MA 02421

                  • USA.Map

                  • Phone: +1 617 503-6500

                  • Fax: +1 617 503-6501

                  • curis.com

                  Incorporated

                  2000

                  Employees

                  33

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: